Management of Acute Kidney Injury in Patients with Myasthenia Gravis

Immediate Assessment and Nephrotoxin Management

In patients with myasthenia gravis who develop acute kidney injury, immediately discontinue all nephrotoxic medications, provide supportive care with isotonic crystalloids for volume expansion, and adjust anticholinesterase dosing based on reduced renal clearance while monitoring closely for myasthenic crisis, as recommended by the American College of Physicians and the National Kidney Foundation 1, 2
Hold all diuretics immediately and discontinue nephrotoxic medications, particularly NSAIDs which are commonly implicated in AKI, according to the American College of Rheumatology 2
Evaluate for recent IV contrast exposure, dehydration, urinary tract infections, and medication-induced causes, as suggested by the American Society of Clinical Oncology 3, 4
Avoid the "triple whammy" combination of NSAIDs, diuretics, and ACE inhibitors/ARBs which dramatically increases AKI risk, as warned by the American Heart Association and the National Kidney Foundation 1, 2

Assess volume status carefully using clinical examination, vital signs, and when indicated, echocardiography or central venous pressure monitoring, as recommended by the Society of Critical Care Medicine 2
Use isotonic crystalloids (not colloids) for volume expansion in hypovolemic patients, according to the American College of Emergency Physicians 2
Avoid aggressive fluid administration in euvolemic or hypervolemic patients, as advised by the National Kidney Foundation 2

Initiate renal replacement therapy for standard indications: severe hyperkalemia, volume overload refractory to diuretics, uremic symptoms, or severe metabolic acidosis, as recommended by the National Kidney Foundation 5, 6
Timing of dialysis in the first 48 hours should account for volume status, electrolyte disturbances, and bleeding potential, according to the American Society of Nephrology 7

Evaluate patients 3 months after AKI for resolution, new onset, or worsening of pre-existing chronic kidney disease, as recommended by the American College of Physicians and the National Kidney Foundation 2
Consider nephrology consultation for Stage 3 or higher AKI, according to the National Kidney Foundation 2
Monitor for delayed recovery, as AKI can have prolonged effects on drug metabolism beyond normalization of creatinine, as noted by the American Society of Nephrology 1

Avoid reflexive kidney biopsy in immune-mediated AKI; if autoimmune nephritis is suspected (as with checkpoint inhibitor therapy), treat empirically with corticosteroids first, as recommended by the American Society of Clinical Oncology 3, 4
Do not overlook infection as both a cause of AKI and a trigger for myasthenic crisis, as warned by the Infectious Diseases Society of America and the National Kidney Foundation 2